BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 28, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 21, 2005
View Archived Issues
HCV-ABXTL-68 shows antiviral activity in liver transplant recipients
Read More
Promising results reported from a phase Ib trial on VX-950 in hepatitis C
Read More
Escitalopram reported effective in patients with obsessive-compulsive disorder
Read More
A new trial announced on Vytorin in patients with acute coronary syndromes
Read More
FG-4592: A selective and potent oral erythropoietic agent from FibroGen
Read More
Preclinical data on GSK's new TRPV1 antagonist
Read More
BNP-054: oral treatment for hypertension
Read More
New data on Novartis' competitive NMDA 1A/2A receptor antagonist
Read More
Adherex outlines development plans for chemoenhancer eniluracil
Read More
SIGA Technologies presents smallpox drug SIGA-246 to WHO
Read More
Hexal launches Labopharm's once-daily tramadol product in Germany
Read More
ID Biomedical securityholders vote to approve acquisition by GSK
Read More
FDA meets to consider pneumococcal conjugate vaccine approvals
Read More
Pancrastatin derivative exhibits potent antitumor activity in vivo but not in vitro
Read More
Actelion and UCB replace license agreement for Zavesca
Read More
SMP-534 effective in treating diabetic nephropathy in db/db mice
Read More
Gene therapy as an adjunct to standard MI treatment
Read More
Pharmion withdraws Vidaza MAA
Read More
SGN-33 begins phase I study for AML and MDS patients
Read More
TMC-125 begins phase III program
Read More
ZC-423: A novel PDB dimer with remarkable antitumor efficacy
Read More
Corgentech and AlgoRx mail definitive proxy for proposed merger
Read More
Tysabri sBLA for MS granted priority review
Read More
Eisai resubmits rufinamide NDA
Read More
Cubicin recommended for approval in Europe
Read More
SERMs described in Council of Scientific and Industrial Research patent
Read More
Recent patents disclose new analgesic agents
Read More
Recent patents report novel treatment options for respiratory disorders
Read More
